For the overall survival (OS) data, different cancer types showed differentialclustering when grouped according to HR values for the ERK1/2 pathways(Fig. 2A).Both pathways generally showed consistent patterns.Specifically, for glioblastoma, kidney, pancreatic, gastric, bladder, lungadenocarcinoma and lung squamous cell carcinoma, activation of both of theERK1/2 molecular pathways was associated with significantly lower patient OSnumbers. This evidence concerns the gene MAPK3 and glioblastoma.